The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Characterization of Severe Asthma Worldwide
Open accessAbstract
BACKGROUND: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region. METHODS: The International Severe Asthma Registry retrospectively and prospectively collected data in patients with severe asthma (≥ 18 years old), receiving Global Initiative for Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA Step 4. Baseline demographic and clinical data were collected from the United States, United Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including Australia, Singapore, and New Zealand) from December 2014 to December 2017. RESULTS: We included 4,990 patients. Mean (SD) age was 55.0 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was observed in clinical characteristics, prescribed treatments, and biomarker profiles. CONCLUSIONS: Using a common data set and definitions, this study describes severe asthma characteristics of a large patient cohort included in multiple severe asthma registries and identifies country differences. Whether these are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/or cultural factors requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationDevelopment of the asthma control test
Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., Murray, J. J., & Pendergraft, T. B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.008 · Cited by 2,906
Lung Function Testing: Selection of Reference Values and Interpretative Strategies
(1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.5.1202 · Cited by 2,510
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Eder, W., Ege, M. J., & von Mutius, E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054308 · Cited by 1,621
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Ortega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Oral corticosteroid exposure and adverse effects in asthmatic patients
Sullivan, P. W., Ghushchyan, V. H., Globe, G., & Schatz, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.009 · Cited by 327
Cited by
Chowdhury, N. U., Guntur, V. P., Newcomb, D. C., & Wechsler, M. E. (2021) · European Respiratory Review · doi:10.1183/16000617.0067-2021 · Cited by 440
Self-citationEosinophilic and Noneosinophilic Asthma
Heaney, L. G., Perez de Llano, L., Al-Ahmad, M., Backer, V., Busby, J., Canonica, G. W., Christoff, G. C., Cosio, B. G., FitzGerald, J. M., Heffler, E., et al. (2021) · Chest · doi:10.1016/j.chest.2021.04.013 · Cited by 282
Self-citationMenzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T., Jackson, D. J., Price, D., Lugogo, N., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00352-0 · Cited by 177
Self-citation
Metadata
- Authors
- Wang, E., Wechsler, M. E., Tran, T. N., Heaney, L. G., Jones, R. C., Menzies-Gow, A. N., Busby, J., Jackson, D. J., Pfeffer, P. E., Rhee, C. K., Cho, Y. S., Canonica, G. W., Heffler, E., Gibson, P. G., Hew, M., Peters, M., Harvey, E. S., Alacqua, M., Zangrilli, J., Bulathsinhala, L., Carter, V. A., Chaudhry, I., Eleangovan, N., Hosseini, N., Murray, R. B., & Price, D. B.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 157
- Issue
- 4
- Pages
- 790-804
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2991287546
- Cited by
- 351
- References
- 41
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of Severe Asthma Worldwide. https://app.cochat.ai/papers/10.1016/j.chest.2019.10.053
- The paper
- Wang, E., Wechsler, M. E., Tran, T. N., Heaney, L. G., Jones, R. C., Menzies-Gow, A. N., Busby, J., Jackson, D. J., Pfeffer, P. E., Rhee, C. K., Cho, Y. S., Canonica, G. W., Heffler, E., Gibson, P. G., Hew, M., Peters, M., Harvey, E. S., Alacqua, M., Zangrilli, J., . . . Price, D. B. (2020). Characterization of Severe Asthma Worldwide. Chest. https://doi.org/10.1016/j.chest.2019.10.053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.